Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
VEGF-KDR (ID# 7624)

Peptide
VEGF-KDR
Tissue
~80 µM (reported value)
Binding Buffer: DMEM supplemented with 20 mM HEPES (pH 7.4) and 2 mg/mL gelatin
4°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Reduces VEGF-induced angiogenesis and blocks VEGF-KDR interaction.
NH2-AlaThrTrpLeuProProArg-COOH

7
886.11
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Binetruy-Tournaire et al. "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis." The EMBO Journal, 19(2000): 1525-1533.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.